Neurology News

The FDA has cleared an investigational new drug application for the start of a phase 2 study of TNX-1900, a nasal spray created to prevent migraine headaches.

With the end of the year approaching and the possibility of tax hikes in 2022 looming, many physicians and their practices are looking at ways to reduce 2021 taxable income.

Intensive blood pressure reduction did not appear to prevent cognitive decline and dementia, according to results of a systematic review and meta-analysis published in JAMA Network Open.

A new software program may help identify Parkinson’s disease, researchers have found.

The BMJ and Cochrane Sustainable Healthcare have jointly launched The Recovery, a new podcast highlighting initiatives that practitioners around the world are using to reduce medical excess.

Health care technology firm Brain Scientific Inc. has announced that LOK Corporation will oversee its U.S. and global distribution network to promote and distribute its neurological instruments.

Neurocrine Biosciences and Sosei Group Corporation have announced a partnership to create a new brand of protein inhibitor that the former plans to study to improve treatments for a wide range of neuropsychiatric disorders.

Healio Neurology’s five most-viewed stories in November highlight the link between inflammatory diets and dementia risk, the role of influenza infection in Parkinson’s disease risk, and regulatory developments.

A personalized cancer vaccine conferred a PFS benefit to a subset of patients with newly diagnosed glioblastoma, according to phase 2 study results presented at Society for the Immunotherapy of Cancer Annual Meeting.

John F. de Groot, MD, has been appointed chief of the neuro-oncology division at University of California, San Francisco.